BDBM434942 (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-4-((1,3-dioxoisoindolin-2-yl)methyl)-5,5a-dihydroxy-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulen-6-yl (4-chlorophenyl) (methyl)carbamate::US10583140, Example 3

SMILES C[C@@H]1C[C@@H]2[C@H]([C@@H]3C=C(CN4C(=O)c5ccccc5C4=O)[C@@H](O)[C@]4(O)[C@@H](OC(=O)N(C)c5ccc(Cl)cc5)C(C)=C[C@@]14C3=O)C2(C)C

InChI Key InChIKey=KLRWFSNUFVAFKM-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 434942   

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434942(US10583140, Example 3 | (1aR,2S,5R,5aS,6S,8aS,9R,1...)
Affinity DataEC50:  1.11E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In DepthDetails Article
US Patent